AU2010249269B2 — Substituted diazepan compounds as orexin receptor antagonists
Assigned to Merck Sharp and Dohme LLC · Expires 2012-02-02 · 14y expired
What this patent protects
Substituted diazepan compounds as orexin receptor antagonists Abstract The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and …
USPTO Abstract
Substituted diazepan compounds as orexin receptor antagonists Abstract The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these 10 compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.